Opinion|Videos|July 17, 2024
Exploring Data Outcomes From the SUNLIGHT Trial
Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.
Advertisement
Episodes in this series
- Briefly summarize the SUNLIGHT trial, evaluating TAS-102 ± bevacizumab in patients with mCRC (
Prager, et al. NEJM, 2023 )
- Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (
Taieb J, et al. ASCO GI 2024. Abstract 111 ) - Dr Benson: What is the impact of colorectal liver metastases (CRLM) in patients with mCRC treated with TAS-102 ± bevacizumab? (
Tabernero J, et al. ASCO 2024. Abstract 3584. )
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5